 | Up a level |
Number of items: 1.
Stelljes, M., Kreuzer, K. -A, Deangelo, D. J., Advani, A. S., Goekbuget, N., Liedtke, M., Stock, W., Martinelli, G., O'Brien, S., Wang, K., Wang, T., Paccagnella, M. L., Sleight, B., Vandendries, E., Jabbour, E. J. and Kantarjian, H. M. (2016). Inotuzumab ozogamicin (InO) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) in the global phase 3 randomized controlled ino-vate trial: efficacy and safety by age and prior therapy. Oncol. Res. Treat., 39. S. 201 - 203. BASEL: KARGER. ISSN 2296-5262